Finance
Novartis to Buy Breast Cancer Drug Candidate From Synnovation
Published by Global Banking & Finance Review®
Posted on March 20, 2026
1 min readLast updated: March 20, 2026
Quick Summary
Novartis has agreed to acquire the experimental PI3Kα inhibitor SNV4818 from Synnovation Therapeutics for $2 billion upfront plus up to $1 billion in contingent payments, targeting HR‑positive/HER2‑negative breast cancer and other solid tumours.
Novartis Acquires Experimental Breast Cancer Drug SNV4818 from Synnovation
Novartis Announces Major Acquisition Deal
Acquisition Details and Financial Terms
FRANKFURT, March 20 (Reuters) - Novartis said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent on further development achievements.
About SNV4818 and Its Therapeutic Potential
Drug Classification and Mechanism
The experimental drug belongs to the class of selective PI3Kα inhibitors, a new approach for the treatment of a type of breast cancer known as HR positive/HER2 negative and potentially other solid tumours.
Implications for Breast Cancer Treatment
(Reporting by Ludwig Burger; Editing by Himani Sarkar)
Key Takeaways
- •Novartis expands its oncology pipeline by licensing SNV4818, a selective PI3Kα inhibitor targeting PIK3CA‑mutant cancers.
- •Deal structure: $2 billion upfront and up to $1 billion in milestones tied to development progress.
- •SNV4818 is in Phase I clinical trials, designed for safety, tolerability and efficacy as monotherapy and in combination with fulvestrant in HR+/HER2‑ breast cancer patients.
Frequently Asked Questions about Novartis to buy breast cancer drug candidate from Synnovation
1What did Novartis acquire from Synnovation?
Novartis agreed to acquire the breast cancer drug candidate SNV4818 from Synnovation Therapeutics.
2How much is Novartis paying for SNV4818?
Novartis will pay $2 billion upfront and up to an additional $1 billion based on development milestones.
3What type of drug is SNV4818?
SNV4818 is an experimental drug classified as a selective PI3Kα inhibitor.
4Which breast cancer types does SNV4818 target?
The drug targets HR positive/HER2 negative breast cancers and potentially other solid tumors.
5Who reported and edited the article?
The article was reported by Ludwig Burger and edited by Himani Sarkar.
